Abstract
Traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a chronic course and an unfavorable outcome. Throughout history, there has been incidence of schizophrenia, roughly one percent of the population, consistently, in every culture. It is generally acknowledged that schizophrenia has multifactorial etiology, with multiple susceptibility genes interacting with environmental insults to yield a range of phenotypes in the schizophrenia spectrum. The discovery of antipsychotics in the 1950s revolutionized the treatment of schizophrenia and focused on the positive symptoms. By the 1960s, however, it became obvious that the reduction in positive symptoms did not lead to recovery from schizophrenia and did not improve the functional outcome significantly. The advent of the novel antipsychotics during the last 15 years represents a significant improvement over the effectiveness of conventional antipsychotics. However, these agents are not a magic bullet and are associated with their own attendant treatment complications, such as weight gain, diabetes, hyperprolactinemia, and QTc prolongation. Nevertheless, at this point, they seem to be more effective and safer than conventional antipsychotics. Moreover, advances in the treatment of schizophrenia have been and continue to be urgently needed.
Keywords: tardive dyskinesia, extrapyramidal effect, antipsychotic, neuroleptics, diabetes, benzodiazepine receptor
Current Drug Therapy
Title: Pharmacotherapy of Schizophrenia: The Past, Present and Future
Volume: 1 Issue: 1
Author(s): Shahin Akhondzadeh
Affiliation:
Keywords: tardive dyskinesia, extrapyramidal effect, antipsychotic, neuroleptics, diabetes, benzodiazepine receptor
Abstract: Traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a chronic course and an unfavorable outcome. Throughout history, there has been incidence of schizophrenia, roughly one percent of the population, consistently, in every culture. It is generally acknowledged that schizophrenia has multifactorial etiology, with multiple susceptibility genes interacting with environmental insults to yield a range of phenotypes in the schizophrenia spectrum. The discovery of antipsychotics in the 1950s revolutionized the treatment of schizophrenia and focused on the positive symptoms. By the 1960s, however, it became obvious that the reduction in positive symptoms did not lead to recovery from schizophrenia and did not improve the functional outcome significantly. The advent of the novel antipsychotics during the last 15 years represents a significant improvement over the effectiveness of conventional antipsychotics. However, these agents are not a magic bullet and are associated with their own attendant treatment complications, such as weight gain, diabetes, hyperprolactinemia, and QTc prolongation. Nevertheless, at this point, they seem to be more effective and safer than conventional antipsychotics. Moreover, advances in the treatment of schizophrenia have been and continue to be urgently needed.
Export Options
About this article
Cite this article as:
Akhondzadeh Shahin, Pharmacotherapy of Schizophrenia: The Past, Present and Future, Current Drug Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157488506775268461
DOI https://dx.doi.org/10.2174/157488506775268461 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Safe and Effective Delivery of Amphotericin B: A Survey of Patents
Recent Patents on Nanotechnology Moderate Hypothermia in the Management of Severe Traumatic Brain Injury: A Good Idea Proved Ineffective?
Current Pharmaceutical Design Therapeutic Potential of Targeting the Endocannabinoids: Implications for the Treatment of Obesity, Metabolic Syndrome, Drug Abuse and Smoking Cessation
Current Medicinal Chemistry Vasorelaxant and Antihypertensive Effects of <i>Mentha pulegium</i> L. in Rats: An In vitro and In vivo Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Usefulness of Magnetic Resonance Imaging in Cardiac and Enovascular Intervention
Current Medical Imaging Downstream Processing of Bioactive Compounds from Milk and Whey
Current Biochemical Engineering (Discontinued) PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Microcirculatory Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs New Anti-Anginal Drugs: Ranolazine
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypertension in Older Patients
Current Hypertension Reviews